The prokaryotic obligate intracellular pathogen Chlamydia trachomatis is the most prevalent cause of preventable blindness, affecting approximately six million people worldwide. In addition, C. trachomatis is the most commonly reported sexually transmitted pathogen in Europe and the US, causing pelvic inflammation, ectopic pregnancy and infertility. As in other intracellular pathogens, proteases play crucial roles during most stages of the complex life cycle of Chlamydia. CT441 is a chlamydial protease that has been reported to interfere with oestrogen signalling of the host cell. Here, the recombinant production, purification and crystallization of an inactive variant of CT441, designated CT441 (active-site Ser455 replaced by Ala), are described. CT441 was crystallized in space group P22 1 2 1 , with unit-cell parameters a = 86.7, b = 184.0, c = 209.6 Å . A complete diffraction data set was collected to a resolution of 2.95 Å .
Introduction
Chlamydiae are Gram-negative obligate intracellular prokaryotes with a wide host range including humans, animals, free-living amoebae and other eukaryotes. C. trachomatis is the most prevalent cause of preventable blindness (affecting six million people worldwide; Mariotti et al., 2009) and the most commonly reported sexually transmitted pathogen in Europe (340 000 reported cases per year) and the US (1.3 million reported cases per year) (Centers for Disease Control and Prevention, 2011; European Centre for Disease Prevention and Control, 2011; Peipert, 2003) . Although C. trachomatis has been recognized as a major healthcare problem worldwide, many aspects of the underlying virulence mechanisms are far from being well understood. During the replication phase, C. trachomatis depends on an extensive modification of host-cell signalling pathways, utilizing a number of virulence factors which are secreted into the hostcell cytosol. CT441 is a chlamydial tail-specific protease (Tsp) with a catalytic serine and a PDZ domain. It has been reported to interfere with the pro-inflammatory NF-B signalling pathway of the host cell, modulating antimicrobial and inflammatory responses Lad, Yang et al., 2007) . However, in subsequent reports, the role of CT441 in the cleavage of NF-B has been questioned (Chen et al., 2012; Christian et al., 2010) . The results presented by Borth et al. (2010) indicate that CT441 is able to modulate the oestrogen-
# 2015 International Union of Crystallography signalling pathway of the host cell by interacting with human SRAP1 (steroid receptor RNA activator protein 1), a coactivator of oestrogen receptor (ER). We have previously reported the biochemical and structural characterization of CT441 (Kohlmann et al., 2015) . Here, we report details of the production, purification, crystallization and X-ray diffraction analysis of an inactive variant of CT441.
Materials and methods

Macromolecule production
Genomic DNA from C. trachomatis L2/Bu/434 was isolated and ct441 lacking the nucleotides encoding the N-terminal signal peptide was cloned into a pQE30 expression vector (Qiagen) modified to contain the lacI gene and a PreScission protease (GE Heathcare) cleavage site. Site-directed mutagenesis to replace the active-site Ser455 by Ala (CT441 ) was performed using the QuikChange kit (Stratagene). CT441 was produced at 22 C by the addition of isopropyl -d-1thiogalactopyranoside (IPTG; final concentration 1 mM) to Escherichia coli C43 (DE3) cells in 2ÂYT medium at an OD 600 of 0.8-1.0. After 16 h, cells were harvested by centrifugation (5000g, 30 min), resuspended in buffer A [50 mM Na 2 HPO 4 , 500 mM NaCl, 20 mM imidazole, 5%(v/v) glycerol pH 8.0] and lysed by sonification. After centrifugation (27 000g, 277 K, 60 min), the supernatant was loaded onto a HisTrap column (GE Healthcare) and CT441 was eluted with buffer A containing 500 mM imidazole. After buffer exchange to 20 mM Tris, 150 mM NaCl, 0.5 mM EDTA, 1 mM DTT pH 7.4, the His 6 tag was removed by incubation with PreScission protease (1:10 molar ratio of protease to CT441 , 24 h, 4 C).
Uncleaved CT441 , His 6 tag and PreScission protease were removed using connected GST and HisTrap columns (GE Healthcare). After dialysis into 20 mM Tris, 150 mM NaCl pH 7.4, the sample was subjected to size-exclusion chromato- 
graphy (HiLoad 16/60 Superdex 200; GE Healthcare; Fig. 1a ). CT441 samples (Fig. 2b) were pooled, concentrated to 2.5 mg ml À1 , analyzed by dynamic light scattering (DLS; Fig. 2c ) using a SpectroSize 300 instrument (Xtal Concepts, Germany) and stored at À80 C. Macromolecule-production information is summarized in Table 1 . CT441 variants 2, 7 and 8 shown in Fig. 2 and CT441 homologues from C. pneumoniae (CPn555), Simkania negevensis and Protochlamydia amoebophila were produced, purified and stored as described for CT441 . CT441 variants 3-6 were found be to insoluble under all expression conditions tested.
Crystallization
CT441 was crystallized using the sitting-drop vapourdiffusion technique in 24-well Cryschem plates (Hampton Research). Equal volumes (5 ml) of protein (2.5 mg ml À1 ) and crystallization solution were mixed and equilibrated against 500 ml reservoir solution (Table 2) . Prior to diffraction experiments, crystals were transferred into cryoprotection solution, mounted in CryoLoops (Hampton Research) and flash-cooled in liquid nitrogen.
Data collection and processing
X-ray diffraction data for several crystal forms of CT441 which had initially been identified during screening were collected using synchrotron radiation on beamline BL14.2 operated by the Joint Berlin MX-Laboratory at the BESSY II electron-storage ring, Berlin-Adlershof, Germany (Mueller et al., 2012) , beamline P11 (DESY) at PETRA III, Hamburg, Germany, beamline ID29 at ESRF, Grenoble, France and beamlines PX I and PX III at SLS, Villigen, Switzerland. The best crystals diffracted X-rays to a resolution of 2.95 Å at 100 K in a nitrogen-gas stream at BESSY II. Diffraction data were indexed, reduced and scaled using XDS (Kabsch, 2010) and SCALA (Evans, 2006) . Data-collection statistics are given in Table 3 .
Results and discussion
To obtain structural information on chlamydial Tsps, plasmids for the high-yield production of mature Tsp proteins from the pathogenic C. trachomatis (CT441) and C. pneumoniae (CPn555), as well as from the chlamydia-like species S. negevensis and P. amoebophila, have been prepared. For each protein an active-site mutant replacing the nucleophilic Ser Table 2 Crystallization.
Crystallization experiments have also briefly been described in Kohlmann et al. (2015) .
Method
Sitting with an Ala was generated to prevent auto-degradation during prolonged crystallization trials. The expression of all constructs was individually optimized by rational variation of proteinproduction conditions such as the E. coli expression strain, broth medium and expression temperature. In addition, seven constructs for CT441 comprising a combination of predicted protein domains (Fig. 2 ) have been prepared and tested for expression in E. coli. Interestingly, the N-terminal residues 22-250 seem to play a crucial role in the structure or folding of CT441, as variants lacking this region were found to form insoluble inclusion bodies during production in E. coli (Fig. 2) . For soluble proteins, large-scale production and purification was initiated. Large amounts of high-quality protein were obtained for CPn555 (10 mg), CT441 (19 mg) and the S. negevensis and P. amoebophila homologues (>5 mg), as well as for the CT441 variants 1 (>100 mg), 2 (20 mg), 7 (30 mg) and 8 (10 mg) (Fig. 2) . The monodispersity of all protein samples was confirmed by dynamic light scattering. Purified proteins were subjected to initial crystallization trials using 672 conditions from commercial crystallization screens (Hampton Research, Molecular Dimensions). Experiments were set up at 20 C using Intelli-Plate 96 plates (Art Robbins Instruments) and a Phoenix robot (Art Robbins Instruments). Out of all of the proteins tested, only full-length CT441 (variant 1) formed crystals in initial crystallization trials. The preliminary conditions were optimized by variation of the concentrations of buffers, divalent cations, polyethylene glycols and ethylene glycol, the temperature and the pH using 24-well Cryschem M plates (Hampton Research). Optimization of protein-production and crystallization conditions (Tables 1 and 2) yielded CT441 crystals with final dimensions of 0.13 Â 0.11 Â 0.08 mm within 2-4 weeks at 293 K (Fig. 3) .
After the identification of a suitable cryoprotection condition (Table 2) , a diffraction data set was collected to a resolution of 2.95 Å at BESSY, Berlin from a crystal belonging to space group P22 1 2 1 , with unit-cell parameters a = 86.7, b = 184.0, c = 209.6 Å (Fig. 4) . The asymmetric unit contains four CT441 molecules with a Matthews coefficient (Matthews, 1968 ) of 2.97 Å 3 Da À1 (estimated solvent content of 58.5%). Full structure determination, refinement and analysis of CT441 together with data on its biological function have been reported elsewhere (Kohlmann et al., 2015) .
Figure 4
X-ray diffraction pattern to a resolution of 2.95 Å acquired on beamline BL14.2 at BESSY, Berlin. 
